Items where Author is "Moncrieff, J."
![[up]](/style/images/multi_up.png)
Up a level
Moncrieff, J. 
ORCID: 0000-0003-1214-6974, Long, M. ORCID: 0000-0002-6920-9676, Priebe, S. ORCID: 0000-0001-9864-3394 , Akther-Robertson, J. ORCID: 0009-0007-1720-6215, Barnes, T. ORCID: 0000-0002-2324-656X, Bray, G. ORCID: 0009-0002-2829-6264, Cooper, R. ORCID: 0000-0002-9735-4731, Crellin, N. ORCID: 0000-0002-9497-5874, Darton, K. ORCID: 0009-0004-2173-6647, Freemantle, N. ORCID: 0000-0001-5807-5740, Freudenthal, R. ORCID: 0000-0002-4859-9636, Gkofa, V. ORCID: 0000-0003-0096-4451, Grünwald, L. ORCID: 0000-0001-7010-871X, Haime, Z. ORCID: 0000-0001-6599-2176, Haynes, N. ORCID: 0009-0003-3123-554X, Horne, R. ORCID: 0000-0002-3068-8438, Horowitz, M. ORCID: 0000-0003-1318-2029, Hunter, R. ORCID: 0000-0002-7447-8934, Johnson, S. ORCID: 0000-0002-2219-1384, Kent, L. ORCID: 0009-0007-5055-0392, Lewis, G. ORCID: 0000-0001-5205-8245, Marston, L. ORCID: 0000-0002-9973-1131, Morant, N. ORCID: 0000-0003-4022-8133, Pinfold, V. ORCID: 0000-0003-3007-8805, Ramsay, G. ORCID: 0000-0002-8999-2549, Smith, R. ORCID: 0000-0003-1330-6669, Stansfeld, J. ORCID: 0000-0002-4491-5523, Stockmann, T. ORCID: 0000-0001-9954-1234 & Vickerstaff, V. ORCID: 0000-0002-3119-670X (2026).
Antipsychotic discontinuation and reduction in people with schizophrenia and multiple-episode psychosis: the RADAR mixed-methods research programme including RCT.
Programme Grants for Applied Research, 14(5),
pp. 1-53.
doi: 10.3310/gjjm0506
Orlando, S., Long, M. ORCID: 0000-0002-6920-9676, Akther-Robertson, J. , Stansfeld, J., Haime, Z., Smith, R., Moncrieff, J. & Morant, N. (2025).
Family and informal carers’ views and experiences of antipsychotic reduction and discontinuation within a medication reduction research trial.
Journal of Mental Health, 35(3),
pp. 295-305.
doi: 10.1080/09638237.2025.2585195
Moncrieff, J., Crellin, N., Stansfeld, J. , Cooper, R., Marston, L., Freemantle, N., Lewis, G., Hunter, R., Johnson, S., Barnes, T., Morant, N., Pinfold, V., Smith, R., Kent, L., Darton, K., Long, M. ORCID: 0000-0002-6920-9676, Horowitz, M., Horne, R., Vickerstaff, V., Jha, M. & Priebe, S. (2023).
Antipsychotic dose reduction and discontinuation versus maintenance treatment in people with schizophrenia and other recurrent psychotic disorders in England (the RADAR trial): an open, parallel-group, randomised controlled trial.
The Lancet Psychiatry, 10(11),
pp. 848-859.
doi: 10.1016/s2215-0366(23)00258-4
Morant, N., Long, M. ORCID: 0000-0002-6920-9676, Jayacodi, S. , Cooper, R., Akther-Robertson, J., Stansfeld, J., Horowitz, M., Priebe, S. & Moncrieff, J. (2023).
Experiences of reduction and discontinuation of antipsychotics: a qualitative investigation within the RADAR trial.
eClinicalMedicine, 64,
article number 102135.
doi: 10.1016/j.eclinm.2023.102135
Ramsay, G., Haime, Z., Crellin, N. E. , Stansfeld, J. L., Priebe, S., Long, M. ORCID: 0000-0002-6920-9676 & Moncrieff, J. (2023).
Recruitment to a trial of antipsychotic reduction: impact of an acceptability study.
BMC Medical Research Methodology, 23(1),
article number 78.
doi: 10.1186/s12874-023-01881-0
Crellin, N. E., Priebe, S., Morant, N. , Lewis, G., Freemantle, N., Johnson, S., Horne, R., Pinfold, V., Kent, L., Smith, R., Darton, K., Cooper, R. E., Long, M. ORCID: 0000-0002-6920-9676, Thompson, J., Gruenwald, L., Freudenthal, R., Stansfeld, J. L. & Moncrieff, J. (2022).
An analysis of views about supported reduction or discontinuation of antipsychotic treatment among people with schizophrenia and other psychotic disorders.
BMC Psychiatry, 22(1),
article number 185.
doi: 10.1186/s12888-022-03822-5
Long, M. ORCID: 0000-0002-6920-9676, Stansfeld, J. L., Davies, N. , Crellin, N. E. & Moncrieff, J. (2022).
A systematic review of social functioning outcome measures in schizophrenia with a focus on suitability for intervention research.
Schizophrenia Research, 241,
pp. 275-291.
doi: 10.1016/j.schres.2022.02.011
Goldsmith, L. ORCID: 0000-0002-6934-1925 & Moncrieff, J. (2011).
The psychoactive effects of antidepressants and their association with suicidality.
Current Drug Safety, 6(2),
pp. 115-121.
doi: 10.2174/157488611795684622